The postprandial dynamics of gastroduodenal zone hormones in patients with metabolic obesity associated or not associated with type 2 diabetes
Background. The main aims of the conservative treatment of metabolic obesity (MО) are weight loss and the prevention of type 2 diabetes. Incretin-based drugs are considered to be effective and safe and stimulate insulin secretion via the β-cells of the pancreas, and are widely used to restore impair...
Guardado en:
Autores principales: | Elena Vital'evna Kirienkova, Mariia Aleksandrovna Vasilenko, Pavel Anatol'evich Zatolokin, Nataliya Ivanovna Mironyuk, Dar'ya Aleksandrovna Skuratovskaia, Larisa Sergeevna Litvinova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d3be2bef7b97498a863648c5dc8d11c5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019) -
The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity
por: Daria A. Skuratovskaia, et al.
Publicado: (2019) -
GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice
por: Nakamura T, et al.
Publicado: (2021) -
Adipokines in metabolic processes regulating during obesity treatment
por: Larisa Sergeevna Litvinova, et al.
Publicado: (2014) -
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)